Cargando…
Exploring SPK98 for the Selective Sensitization of ATM- or P53-Deficient Cancer Cells
[Image: see text] Frequent mutation in the ATM/P53 signaling pathway has been documented in many human cancers. Reportedly, cancer cells with deficient P53/ATM pathways depend on functional Ataxia-telangiectasia and Rad3-related (ATR) protein for survival. This has prompted research in developing AT...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909806/ https://www.ncbi.nlm.nih.gov/pubmed/36777575 http://dx.doi.org/10.1021/acsomega.2c07356 |
_version_ | 1784884653242449920 |
---|---|
author | Priya, Bhanu Dubey, Gurudutt Kirubakaran, Sivapriya |
author_facet | Priya, Bhanu Dubey, Gurudutt Kirubakaran, Sivapriya |
author_sort | Priya, Bhanu |
collection | PubMed |
description | [Image: see text] Frequent mutation in the ATM/P53 signaling pathway has been documented in many human cancers. Reportedly, cancer cells with deficient P53/ATM pathways depend on functional Ataxia-telangiectasia and Rad3-related (ATR) protein for survival. This has prompted research in developing ATR inhibitors for the selective sensitization of cancer cells that are P53/ATM-deficient, but no clinical success has been attained thus far. This study explores the therapeutic potential of SPK98, an analogue of Torin2 in P53- and ATM-deficient cancer cells. Furthermore, the prospect of improving the therapeutic outcome of the genotoxic agent was also explored. SPK98 was shown to inhibit full-length human ATR protein purified from HEK293T cells. Cellular investigation using SPK98 demonstrated that it selectively sensitizes P53- and ATM-deficient cells at low concentrations compared to P53-/ATM-proficient cells. Furthermore, SPK98 drives the cancer cells toward cell death by promoting the formation of DNA double-strand breaks. Taken together, our findings suggest that SPK98 is a promising therapeutic molecule for P53- or ATM-deficient malignancy that merits additional preclinical investigation. |
format | Online Article Text |
id | pubmed-9909806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-99098062023-02-10 Exploring SPK98 for the Selective Sensitization of ATM- or P53-Deficient Cancer Cells Priya, Bhanu Dubey, Gurudutt Kirubakaran, Sivapriya ACS Omega [Image: see text] Frequent mutation in the ATM/P53 signaling pathway has been documented in many human cancers. Reportedly, cancer cells with deficient P53/ATM pathways depend on functional Ataxia-telangiectasia and Rad3-related (ATR) protein for survival. This has prompted research in developing ATR inhibitors for the selective sensitization of cancer cells that are P53/ATM-deficient, but no clinical success has been attained thus far. This study explores the therapeutic potential of SPK98, an analogue of Torin2 in P53- and ATM-deficient cancer cells. Furthermore, the prospect of improving the therapeutic outcome of the genotoxic agent was also explored. SPK98 was shown to inhibit full-length human ATR protein purified from HEK293T cells. Cellular investigation using SPK98 demonstrated that it selectively sensitizes P53- and ATM-deficient cells at low concentrations compared to P53-/ATM-proficient cells. Furthermore, SPK98 drives the cancer cells toward cell death by promoting the formation of DNA double-strand breaks. Taken together, our findings suggest that SPK98 is a promising therapeutic molecule for P53- or ATM-deficient malignancy that merits additional preclinical investigation. American Chemical Society 2023-01-30 /pmc/articles/PMC9909806/ /pubmed/36777575 http://dx.doi.org/10.1021/acsomega.2c07356 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Priya, Bhanu Dubey, Gurudutt Kirubakaran, Sivapriya Exploring SPK98 for the Selective Sensitization of ATM- or P53-Deficient Cancer Cells |
title | Exploring SPK98 for the Selective Sensitization of
ATM- or P53-Deficient Cancer Cells |
title_full | Exploring SPK98 for the Selective Sensitization of
ATM- or P53-Deficient Cancer Cells |
title_fullStr | Exploring SPK98 for the Selective Sensitization of
ATM- or P53-Deficient Cancer Cells |
title_full_unstemmed | Exploring SPK98 for the Selective Sensitization of
ATM- or P53-Deficient Cancer Cells |
title_short | Exploring SPK98 for the Selective Sensitization of
ATM- or P53-Deficient Cancer Cells |
title_sort | exploring spk98 for the selective sensitization of
atm- or p53-deficient cancer cells |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909806/ https://www.ncbi.nlm.nih.gov/pubmed/36777575 http://dx.doi.org/10.1021/acsomega.2c07356 |
work_keys_str_mv | AT priyabhanu exploringspk98fortheselectivesensitizationofatmorp53deficientcancercells AT dubeygurudutt exploringspk98fortheselectivesensitizationofatmorp53deficientcancercells AT kirubakaransivapriya exploringspk98fortheselectivesensitizationofatmorp53deficientcancercells |